高11-酮睾酮与复发性非转移性前列腺癌更短的去势抵抗时间相关
研究对145例术后生化复发并接受雄激素剥夺治疗达去势睾酮水平的前列腺癌患者,用质谱法检测血浆11-氧雄激素。11-酮睾酮(11KT)水平高于中位数273 pg/mL与更短的去势抵抗性前列腺癌(CRPC)时间相关(P=0.03),多变量校正HR为2.17(95%CI 0.99-4.71;P=0.05)。
要点
- 11KT是最丰富的雄激素,但未与临床特征相关。
- 11KT水平高于中位数273 pg/mL者CRPC时间更短(P=0.03)。
- 多变量分析中11KT与CRPC风险关联的校正HR为2.17(95%CI 0.99-4.71;P=0.05)。
核心结论
- 11KT是预测CRPC更早发生的激素谱中的关键组成部分。
- 加深对11KT在CRPC进展中特定作用的理解,可能有助于优化对去势敏感性前列腺癌患者和CRPC患者的激素治疗。
研究设计与样本
- 用质谱法对145例术后血浆样本进行11-氧雄激素定量,这些患者随后因生化复发接受雄激素剥夺治疗并达到去势睾酮水平。
- 采用Kaplan-Meier生存分析和多变量Cox模型研究类固醇与CRPC之间的关系。
主要发现
- 145例患者中31例发生CRPC,中位至CRPC时间为57个月。
- 11-氧雄激素水平不受雄激素剥夺治疗影响,这与观察到的睾酮和其他类固醇的变化形成对比。
- 11KT是最丰富的雄激素,但未与临床特征相关。
- Kaplan-Meier分析显示,11KT水平高于中位数273 pg/mL与更短的至CRPC时间相关(P=0.03)。
- 多变量分析中校正HR为2.17(95%CI 0.99-4.71;P=0.05)。
关键数值与推荐
- 11KT中位数为273 pg/mL;高于该中位数的11KT水平与更短至CRPC时间相关(P=0.03)。
- 多变量分析中11KT与CRPC关联的校正HR为2.17(95%CI 0.99-4.71;P=0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多变量分析中校正HR的95%CI为0.99-4.71,P=0.05。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The contribution of 11-oxygenated androgens to the progression of lethal prostate cancer (PCa) remains unresolved. We hypothesized that evaluating circulating levels of 11-oxygenated androgens, such as the androgen receptor agonist 11-ketotestosterone (11KT), could serve as a potential predictor of the onset of castration-resistant PCa (CRPC). MATERIALS AND METHODS: We used mass spectrometry to quantify 11-oxygenated androgens in postoperative plasma samples acquired from 145 patients who subsequently received androgen deprivation therapy for biochemical recurrence and achieved castrated testosterone levels. Kaplan-Meier survival analyses and multivariable Cox models were used to investigate relationships between steroids and CRPC. RESULTS: Of 145 patients, 31 developed CRPC with a median time to CRPC of 57 months. 11-Oxygenated androgen levels were unaffected by androgen deprivation therapy, which stands in contrast to the observed changes in testosterone and other steroids. 11KT was the most abundant androgen but was not linked to clinical features. Kaplan-Meier analysis revealed that 11KT levels above the median of 273 pg/mL were associated with a shorter time to CRPC (P = .03). In multivariable analyses, this was supported with an adjusted HR of 2.17 (95% CI, 0.99-4.71; P = .05). CONCLUSIONS: 11KT is a key component of the hormonal profile predictive of earlier onset of CRPC. Enhancing our understanding of the specific role of 11KT in the progression to CRPC could help optimize hormonal therapy for castration-sensitive patients with PCa and CRPC.
引用
- Dahmani C, Caron P, Simonyan D, et al. High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer. J Urol. 2024. PMID: 39546743. doi:10.1097/JU.0000000000004333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。